MARKET WIREYahoo Finance • 13h ago
Tilray Brands: Is the Stock a Buy at Less Than $4?Yahoo Finance report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
Why TLRY Stock dropped -4.17% Today — RQD Quant Desk Flash
$2.53 -4.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.51
Tilray Brands Inc. (TLRY) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $390.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TLRY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $2.53 (-4.17% 1D, market cap $390.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLRY ranks #988 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TLRY compare to OBIO and SNDL in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TLRY?
▼
Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.51 (-0.94%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLRY)Realized 20D OHLCV Swing Band: ±10.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY TLRY SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (40% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.4% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.36-9.8% Next Q
28
Q2 (-2Q)Grade E$3.03-10.2% Next Q
25
Q3 (-1Q)Grade E$2.72-7% Next Q
23
CurrentGrade E$2.53-11.8% Hist 90D α
20
Trajectory: E (28) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TLRY Turnaround Squeeze
While TLRY currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.75) and Max Pain ($2.66) forces dealer call-delta covering toward $16.48.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLRY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLRY Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TLRY Stock dropped -4.17% Today — RQD Quant Desk Flash
Tilray Brands Inc. (TLRY) dropped -4.17% to $2.53, trading at 2% of its 52-week range ($2.49 – $15.7). Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.49 – $15.7) with RSI-14 at 25.8 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.5% around $2.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 28.4% gross margin and $0 annual free cash flow.
Live TLRY Headlines & Catalysts
CATALYST24/7 Wall St. • 16h ago
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease24/7 Wall St. report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 22h ago
Tilray Brands, Inc. Stock (TLRY) - Quote Nasdaqmarketscreener.com report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 1d ago
Tilray Brands, Inc. (TLRY) stock price, news, quote and historyYahoo Finance Singapore report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTThe Motley Fool • 1d ago
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?The Motley Fool report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 1d ago
3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock PricesThe Motley Fool report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 17h ago
Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable GrowthConsolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings Higher Cultivation Yields and Expected Ree
MARKET WIREBenzinga • 21h ago
Tilray Brands Plans To Consolidate Canadian Cannabis Operations, Transitioning Cultivation And Pre-Roll Production From Foss Facility In Fenwick, Ontario To Masson, Quebec And Cayuga, Ontario FacilitiesConsolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost SavingsHigher Cultivation Yields and Expected
MARKET WIREYahoo • 1d ago
Forget U.S. Rescheduling: Tilray's 71% Growth in Europe Is the Story Investors Are MissingTilray's ambition to move beyond marijuana has hit high gear, and it changes the company's story in a big way.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLRY)
- ✓Walkthrough of TLRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TLRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.12%▼ DESCENDING CHANNEL
2026-11-02O $2.69H $2.69L $2.53C $2.53VOL 4.21M
RES: $4.35SUP: $1.69SMA50: $3.75SMA200: $5.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TLRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TLRY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TLRY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLRY)
Health Care Rank #988 of 1016
⚔️ OBIO vs TLRY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TLRY vs. OBIO, SNDL, CGC, USNA)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tilray Brands Inc. (TLRY) ranks #988 by composite RQD confidence (20/100, grade E) and #484 by equity capitalization ($390.2M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with TLRY at 20/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TLRY
ACTIVE
Tilray Brands Inc. | E | 20/100 | — | 28.4% | -3.9% | -4.17% | $390.2M | Benchmark Subject |
| OBIO Orchestra BioMed Holdings Inc. | D- | 36/100 | — | 96.0% | -35.0% | -2.96% | $366.0M | /obio-vs-tlry → |
| SNDL SNDL Inc. | D | 48/100 | — | — | — | -4.61% | $316.3M | /sndl-vs-tlry → |
| CGC Canopy Growth Corporation | D- | 41/100 | — | — | — | -3.33% | $285.6M | /cgc-vs-tlry → |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | -0.21% | $265.0M | /usna-vs-tlry → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001731348In its most recent audited fiscal period (FY2025, filed 2026-05-31), Tilray Brands Inc. (TLRY) reported GAAP revenue of $915.5M (+11.5% vs. FY2024 revenue of $821.3M , and +16.0% cumulative change since FY2023) , GAAP net income of -$121.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (+26.9% YoY). On the balance sheet, TLRY closed FY2025 with $2.07B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-05-31 | $915.5M | -$121.4M | -$69.1M | -$69.1M | $2.07B | — |
| FY2024 (FY) | 2025-05-31 | $821.3M | -$2.19B | -$94.6M | -$94.6M | $3.40B | — |
| FY2023 (FY) | 2024-05-31 | $788.9M | -$245.0M | -$30.9M | -$30.9M | — | — |
3. TLRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $2.53 (-4.17% 1D, market cap $390.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLRY ranks #988 in composite RQD confidence.
How does TLRY compare to OBIO and SNDL in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TLRY?
Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TLRY trading relative to its 50-day, 200-day, and 52-week technical levels?
TLRY last traded at $2.53 (-4.17% on volume of 4,931,025 shares), positioning the stock -32.53% below its 50-day simple moving average ($3.75) and -53.49% below its 200-day simple moving average ($5.44). Across its 52-week range of $2.49 to $15.70, TLRY sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±10.5% ($2.26 to $2.80).
TLRY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TLRY stock moving today?
Why TLRY Stock dropped -4.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 20/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
TLRY — Tilray Brands Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:10Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, TLRY carries an RQD Score of 20 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 2/20 (ROIC -3.9%; FCF yield -17.72%); Whale 13F Flow scores 3/20 (institutional accumulation and options positioning); Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 4/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet scores 8/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the cash engine and the insider/institutional flow signals, both of which sit at the low end of the scale. The forensic balance sheet pillar is the strongest of the five, yet its score of 8/20 still reflects a low Altman Z of 0.2, which the rating frames as a distress-zone reading. The macro pillar is neutral-to-weak, with a beta of 1.0 meaning the stock moves in line with the broader market rather than offering a defensive or amplified profile. Upside drivers would need to come from a durable improvement in free cash flow and returns on capital, neither of which the current data shows. Valuation cannot be assessed on earnings multiples because P/E and EPS are not available in source data, so the investment case rests on whether the forensic and cash-generation metrics can reverse.
Business
Tilray Brands Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile identifies the company as having a market capitalization of $0.4B. Customer base, product lines, and revenue mix are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $915.5M | $-63.0M | $-121.4M | N/A | $-69.1M | $221.7M | N/A |
| FY 2024 | $821.3M | $-2282.7M | $-2186.7M | N/A | $-94.6M | $200.0M | N/A |
| FY 2023 | $788.9M | $-174.7M | $-245.0M | N/A | $-30.9M | N/A | N/A |
Per the SEC financials, revenue rose from $788.9M in FY 2023 to $915.5M in FY 2025, while operating and net losses persisted across all three reported periods. Per the market data, gross margin is 28.4%, operating margin is -6.9%, and net margin is -13.3%, with ROIC at -3.9%. The forensic balance sheet inputs include an Altman Z-Score of 0.2 and a Piotroski F-Score of 5/9, alongside a Debt/Equity ratio of 0.5, per the Roarable RQD rating. Reported cash of $221.7M in FY 2025 is shown against negative free cash flow of $-69.1M in the same period.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, six items relate to TLRY. Headlines include "Tilray Brands: Is the Stock a Buy at Less Than $4?" (Yahoo Finance and The Motley Fool), "Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease" (24/7 Wall St.), "Tilray Brands, Inc. Stock (TLRY) - Quote Nasdaq" (marketscreener.com), "Tilray Brands, Inc. (TLRY) stock price, news, quote and history" (Yahoo Finance Singapore), and "Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?" (The Motley Fool). Two items are tagged CATALYST and carry a GREEN light; four are tagged MARKET WIRE with YELLOW lights. The most explicit fundamental datapoint in the headlines is the contrast between record revenue and shrinking cannabis sales, a risk-watch item. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and cross-sector dependencies are therefore not available in source data. Sector correlation and second-order bottlenecks cannot be mapped from the provided material. The only sector context available is the Health Care classification and the Medicinal Chemicals and Botanical Products industry, per the profile. An investor should treat the absence of mapped supply-chain links as an open gap rather than evidence of an absence of exposure.
Open Questions
- What is the reported EPS and the P/E ratio, given that both are unavailable in the source data and the cash-flow picture is negative?
- What are the drivers of the revenue gap between record total revenue and the shrinking cannabis sales referenced in the news feed?
- What is the composition of the FY 2025 $221.7M cash balance, and what debt obligations sit against it, given that debt is listed as N/A?
- What explains the FY 2024 net loss of $-2186.7M, and does that figure reflect a one-time or recurring charge?
- Who are the 13F holders and insiders behind the institutional and insider pillar scores, since holder data is not provided?
TLRY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Tilray Brands Inc. (TLRY) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 13h ago
Tilray Brands: Is the Stock a Buy at Less Than $4? Yahoo Finance report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST 24/7 Wall St. • 16h ago
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease 24/7 Wall St. report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 22h ago
Tilray Brands, Inc. Stock (TLRY) - Quote Nasdaq marketscreener.com report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago
Tilray Brands, Inc. (TLRY) stock price, news, quote and history Yahoo Finance Singapore report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST The Motley Fool • 1d ago
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026? The Motley Fool report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates Yahoo Finance report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices The Motley Fool report covering Tilray Brands Inc. (TLRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 17h ago
Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable Growth Consolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings Higher Cultivation Yields and Expected Ree
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TLRY Bull vs. Bear Conversation Board — What's Your Call at $2.53?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLRY 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.32 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is TLRY (E • RQD 20/100) a Buy at $2.64?
Welcome to the TLRY (Tilray Brands Inc.) Roar Pit. Current RQD Composite is 20/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.16 (-18.2%)
Spot @ $2.64 Pump the brakes on TLRY — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on TLRY, but look at what you are paying: current EV/EBITDA multiples with 28.4% gross margins. Unless Tilray Brands Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.06 (+15.9%)
Spot @ $2.64 TLRY cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on TLRY, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $2.64 (52-wk range $2.49 - $15.70), any beat on forward guidance forces shorts and underweight funds to chase.